New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

Efimosfermin is a long-acting engineered variant of FGF21 designed to have a prolonged half-life, the authors noted, and has ...

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), AstraZeneca ...

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

Understand every aspect of the global economy – and know how to make your next move.

AstraZeneca PLC closed 17.61% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca PLC ADR closed 14.46% short of its 52-week high of $87.68, which the company reached on August 30th.

Ousted CDC vaccine adviser says RFK Jr.’s message is clear: ‘Scientific expertise is no longer of use’ ...

Vice Chancellor Morgan T. Zurn for the second time found Alexion liable to Shareholder Representative Services, the Quinn ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...